Key result
Clozapine initiation is linked to suspected myocarditis or cardiomyopathy in ~10% of patients.
Why the study?
The incidence and clinical features of clozapine-related myocarditis and cardiomyopathy remain uncertain, with variable reported rates and limited data on management and rechallenge.
What is the incidence and diagnostic likelihood of clozapine-related myocarditis and cardiomyopathy in patients initiated on clozapine?
Observational (n=94)
No
What is the incidence and diagnostic likelihood of clozapine-related myocarditis and cardiomyopathy in patients initiated on clozapine?
This case series highlights an unexpectedly high incidence of clozapine-related myocarditis in a single center and suggests that clozapine rechallenge may be a viable option for some patients.
Answers are grounded in this paper and cite their sources.
Supports closer cardiac surveillance with clozapine initiation; leaves open true incidence and rechallenge safety.
Objectives: Myocarditis and cardiomyopathy are rarely reported complications of clozapine treatment. The incidence of clozapine-related myocarditis has been variably reported at between 0.03% and 0.19% of initiations and cardiomyopathy has been reported even less commonly. In our Brisbane-based service, nine of 94 patients initiated on clozapine over the previous 3 years appeared to have experienced myocarditis or cardiomyopathy. The unique co-location of our service with a major cardiothoracic hospital facilitated a review of identified cases to inform decisions regarding clozapine treatment and rechallenge in this service. Method: Cases were identified by survey of psychiatric and cardiac medical staff at The Prince Charles Hospital and subjected to re-evaluation by a multidiscipline consensus panel. The panel compared cases to international reports and identified the clinical features that supported a diagnosis of clozapine-related myocarditis or cardiomyopathy. Results: This process resulted in the stratification of the nine cases into the following categories of diagnostic likelihood: three highly probable, three probable, and two possible cases of clozapine-related myocarditis, and one possible case of clozapine-related cardiomyopathy. Successful clozapine rechallenge/continuation was undertaken in two patients and the panel agreed that this was a viable future option for several other patients. Conclusions: Findings of the panel review supported the initial clinical diagnoses. This confirmed that there was an apparent high incidence of clozapine-related myocarditis within this service, for which there was no clear reason. Mechanisms underlying clozapine-related myocarditis and cardiomyopathy, as well as successful clozapine continuation and rechallenge were considered, but definitive explanations remain unknown. This review highlighted the clinician's role in post-marketing drug surveillance to guide rational management of suspected adverse drug effects.
No takes yet. Share an insight, caveat, or question.
Reinders et al. (2004) conducted an observational in Clozapine-related myocarditis and cardiomyopathy (n=94). Clozapine was evaluated on Clozapine-related myocarditis or cardiomyopathy. Clozapine initiation was associated with suspected myocarditis or cardiomyopathy in 9 of 94 patients, representing an unexpectedly high incidence in this Australian psychiatric service.
Synapse has enriched 10 related papers. Consider them for comparative context: